![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Thursday, June 05, 2014 7:24:38 PM
..........that in his opinion CEO made the correct and bold move by restructuring the crux of this company by moving into the compounding drug niche. It would not surprise me if CEO were looking for other companies similar to Main Avenue to acquire..........and let us not forget our other revenue streams. I would agree with my fellow longs that we can easily be between $1.50-$2 given the numbers company is doing on compounding alone and then factor in the other revenue streams. This is a long term hold and an excellent buy at this price
FEATURED POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM
ECGI Holdings Targets $9.7 Billion Equestrian Apparel Market with Allon Brand Launch • ECGI • Jun 25, 2024 8:36 AM
Avant Technologies Addresses Progress on AI Supercomputer-Driven Data Centers • AVAI • Jun 25, 2024 8:00 AM
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM